NEWS
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
T2 Biosystems (NASDAQ: TTOO) has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH) for the distribution of its FDA-cleared direct-from-blood diagnostics for rapid sepsis detection. The agreement covers the T2Dx® Instrument, T2Bacteria® Panel, and T2Candida® Panel. This collaboration is expected to significantly expand T2 Biosystems' access to the U.S. hospital market.
T2 Biosystems' technology can detect sepsis-causing pathogens directly from blood in 3-5 hours, without waiting for blood culture results. The T2Bacteria Panel detects six pathogens responsible for nearly 75% of U.S. bacterial bloodstream infections, while the T2Candida Panel detects five Candida species accounting for up to 95% of U.S. Candida bloodstream infections. Both panels demonstrate high sensitivity and
T2 Biosystems' technology can detect sepsis-causing pathogens directly from blood in 3-5 hours, without waiting for blood culture results. The T2Bacteria Panel detects six pathogens responsible for nearly 75% of U.S. bacterial bloodstream infections, while the T2Candida Panel detects five Candida species accounting for up to 95% of U.S. Candida bloodstream infections. Both panels demonstrate high sensitivity and
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1778Followers
98Following
14KVisitors
Follow